FDA approves Apretude, first injectable PrEP treatment to lower risk of HIV

The FDA approved the use of Apretude, the first injectable PrEP treatment to lower the risk of HIV infection for at-risk groups. The drug, which is meant to be given every two months, is the first option for preventing HIV that does not involve a daily medication.

Leave a Reply